The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
Main Authors: | Petra Belohlavkova, Filip Vrbacky, Jaroslava Voglova, Zdenek Racil, Daniela Zackova, Katerina Hrochova, Jana Malakova, Jiri Mayer, Pavel Zak |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2018-02-01
|
Series: | Archives of Medical Science |
Subjects: | |
Online Access: | https://www.termedia.pl/The-significance-of-enzyme-and-transporter-polymorphisms-for-imatinib-plasma-levels-and-achieving-an-optimal-response-in-chronic-myeloid-leukemia-patients,19,31830,1,1.html |
Similar Items
-
Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01) -
OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01) -
Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01) -
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01) -
Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
by: Bassam Francis Matti, et al.
Published: (2013-12-01)